SALE
市場調查報告書

胰島素注射液的全球市場:2025年前的各適應症,不同品牌,各給藥途徑,種類別,各作用時間,各產品,不同地區的預測和機會

Global Human Insulin Market By Indication, By Brand, By Route of Administration, By Type, By Onset Time, By Products, By Region, Forecast & Opportunities, 2025

出版商 TechSci Research 商品編碼 934750
出版日期 內容資訊 英文 121 Pages
商品交期: 請詢問到貨日
價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

胰島素注射液的全球市場:2025年前的各適應症,不同品牌,各給藥途徑,種類別,各作用時間,各產品,不同地區的預測和機會 Global Human Insulin Market By Indication, By Brand, By Route of Administration, By Type, By Onset Time, By Products, By Region, Forecast & Opportunities, 2025
出版日期: 2020年05月01日內容資訊: 英文 121 Pages
簡介

本報告提供全球人胰島素市場調查,提供各地區市場展望,市場力學,主要的趨勢,競爭情形等資訊,並提供策略性建議。

目錄

第1章 產品概要

第2章 調查手法

第3章 全球胰島素注射液市場上COVID-19的影響

第4章 摘要整理

第5章 客戶的迴響

第6章 胰島素注射液市場展望

  • 市場規模與預測
  • 市場佔有率與預測
    • 各適應症(I型糖尿病,II型糖尿病)
    • 不同品牌(Humulin R,Novolin R,Humlin N,Exvera,Afleza和Novolin N)
    • 各給藥途徑(皮下,經鼻,靜脈內,經皮,口服,其他)
    • 各類型(基本,推注,預混,生物仿製藥,傳統)
    • 各作用時間(急速作用,短效,中效,長效,超長效,混合前,吸入)
    • 各產品(胰島素筆針,胰島素幫浦,輸液設備,注射)
    • 各公司(2019)
    • 各地區
  • 市場魅力指數

第7章 亞太地區的人的胰島素市場展望

  • 市場規模與預測
  • 市場佔有率與預測
    • 各適應症
    • 不同品牌
    • 各給藥途徑
    • 各類型
    • 各作用時間
    • 各產品
    • 各國
  • 市場魅力指數
  • 亞太地區:國家分析
    • 中國的胰島素注射液市場展望
    • 印度的胰島素注射液市場展望
    • 日本的胰島素注射液市場展望
    • 韓國的胰島素注射液市場展望
    • 新加坡的胰島素注射液市場展望
    • 澳洲的胰島素注射液市場展望

第8章 歐洲的胰島素注射液的市場展望

  • 市場規模與預測
    • 價值及數量
  • 市場佔有率與預測
    • 各適應症
    • 不同品牌
    • 各給藥途徑
    • 各類型
    • 各作用時間
    • 各產品
    • 各國
  • 市場魅力指數
  • 歐洲:國家分析
    • 法國的胰島素注射液市場展望
    • 德國的胰島素注射液市場展望
    • 英國的胰島素注射液市場展望
    • 義大利的胰島素注射液市場展望
    • 俄羅斯的胰島素注射液市場展望
    • 西班牙的胰島素注射液市場展望

第9章 北美的胰島素注射液的市場展望

  • 市場規模與預測
    • 價值及數量
  • 市場佔有率與預測
    • 各適應症
    • 不同品牌
    • 各給藥途徑
    • 各類型
    • 各作用時間
    • 各產品
    • 各國
  • 市場魅力指數
  • 北美:國家分析
    • 美國的胰島素注射液市場展望
    • 墨西哥的胰島素注射液市場展望
    • 加拿大的胰島素注射液市場展望

第10章 南美的人的胰島素市場展望

  • 市場規模與預測
    • 價值及數量
  • 市場佔有率與預測
    • 各適應症
    • 不同品牌
    • 各給藥途徑
    • 各類型
    • 各作用時間
    • 各產品
    • 各國
  • 市場魅力指數
  • 南美:國家分析
    • 巴西的胰島素注射液市場展望
    • 阿根廷的胰島素注射液市場展望
    • 哥倫比亞的胰島素注射液市場展望

第11章 中東及非洲的人的胰島素市場展望

  • 市場規模與預測
    • 價值及數量
  • 市場佔有率與預測
    • 各適應症
    • 不同品牌
    • 各給藥途徑
    • 各類型
    • 各作用時間
    • 各產品
    • 各國
  • 市場魅力指數
  • 中東·非洲地區:國家分析
    • 南非的胰島素注射液市場展望
    • 沙烏地阿拉伯的胰島素注射液市場預測
    • UAE胰島素注射液市場展望

第12章 市場動態

  • 促進因素
  • 挑戰

第13章 市場趨勢

第14章 競爭情形

  • 競爭的展望
  • 主要企業的簡介
    • Nektar Therapeutics
    • MannKind Corporation
    • Novo Nordisk
    • Physicians Total Care, Inc.
    • Eli Lilly and Company
    • A-S Medication Solutions
    • REMEDYREPACK INC.
    • Sedico Co.
    • Sanofi Aventis
    • Pfizer Inc.
    • PerkinElmer
    • Merck
    • Biocon
    • Wockhardt
    • Julphal
    • Ypsomed AG
    • Becton Dickinson and Company
    • B. Braun Melsungen AG
    • Baxter
    • Tandem Diabetes Care, Inc.

第15章 策略性推薦事項

第16章 免責聲明

目錄
Product Code: 4637

Global human insulin market is expected to grow at a steady CAGR during forecast period. Growing geriatric population and increasing incidents of diabetic cases around globe are contributing to the growing demand for human insulin market, globally. Now a days, diabetes is not only restricted to geriatric population, but it is also common among youth. Also, the technological advancements have eradicated human physical activities leading to obesity and diabetes disorders which is directly influencing the growth of the market. Cost effectiveness can be considered as a major restraining factor for the market as everyone suffering from diabetes might not be able to afford insulin.

The global human insulin market is segmented on the basis of indication, brand, route of administration, type, onset type, products and region. Based on indication, market can be bifurcated into type I diabetes and type II diabetes. Type II diabetes is likely to hold the largest market share until 2025 as around 90% of the overall population has type II diabetes.

Based on regional analysis, North America dominated the human insulin market in 2019 due to large population base suffering from diabetes and presence of leading companies in countries like US and Canada.

Leading players in the global human insulin market include Nektar Therapeutics, MannKind Corporation, Novo Nordisk, Physicians Total Care, Inc., Eli Lilly and Company, A-S Medication Solutions, REMEDYREPACK INC., Sedico Co., Sanofi Aventis, Pfizer Inc., PerkinElmer, Merck, Biocon, Wockhardt, Julphal, Ypsomed AG, Becton Dickinson and Company, B. Braun Melsungen AG, Baxter and Tandem Diabetes Care, Inc., among others.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021-2025

Objective of the Study

  • To analyze and forecast the market size of global human insulin market.
  • To classify and forecast global human insulin market based on indication, brand, route of administration, type, onset type, products and region.
  • To identify drivers and challenges for global human insulin market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global human insulin market.
  • To conduct pricing analysis for global human insulin market.
  • To identify and analyze the profile of leading players operating in global human insulin market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of hospitals/clinics across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the hospitals/clinics which could not be identified due to the limitations of secondary research. TechSci Research analyzed the hospitals/clinics and presence of all major players across the globe.

TechSci Research calculated the market size of global human insulin market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience

  • Hospitals/clinics, research institutes and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to human insulin
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as hospitals/clinics, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope

In this report, global human insulin market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Market, By Indication:

Type I Diabetes

Type II Diabetes

  • Market, By Brand:

Humulin R

Novolin R

Humulin N

Exubera

Afrezza

Novolin N

  • Market, By Route of Administration:

Subcutaneous

Nasal

Intravenous

Transdermal

Oral

Others

  • Market, By Type:

Basal

Bolus

Pre-mixed

Biosimilar

Traditional

  • Market, By Onset Time:

Rapid acting

Short-acting,

Intermediate acting

Long acting

Ultra-long acting

Pre-mixed

Inhaled

  • Market, By Products:

Insulin Pens

Insulin Pumps

Infusion System

Injection

  • Market, By Region:

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Singapore
  • Australia

Europe

  • France
  • Germany
  • United Kingdom
  • Italy
  • Russia
  • Spain

North America

  • United States
  • Mexico
  • Canada

South America

  • Brazil
  • Argentina
  • Colombia

Middle east & Africa

  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global human insulin market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Human Insulin Market

4. Executive Summary

5. Voice of Customer

6. Global Human Insulin Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value & Volume
  • 6.2. Market Share & Forecast
    • 6.2.1. By Indication (Type I Diabetes, Type II Diabetes)
    • 6.2.2. By Brand (Humulin R, Novolin R, Humulin N, Exubera, Afrezza, Novolin N)
    • 6.2.3. By Route of administration (Subcutaneous, Nasal, Intravenous, Transdermal, Oral and Others)
    • 6.2.4. By Type (Basal, Bolus, Pre-mixed, Biosimilar, Traditional)
    • 6.2.5. By Onset Time (Rapid Acting, Short-Acting, Intermediate Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled)
    • 6.2.6. By Products (Insulin Pens, Insulin Pumps, Infusion System, Injection)
    • 6.2.7. By Company (2019)
    • 6.2.8. By Region
  • 6.3. Market Attractiveness Index

7. Asia-Pacific Human Insulin Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Indication
    • 7.2.2. By Brand
    • 7.2.3. By Route of Administration
    • 7.2.4. By Type
    • 7.2.5. By Onset Time
    • 7.2.6. By Products
    • 7.2.7. By Country
  • 7.3. Market Attractiveness Index
  • 7.4. Asia-Pacific: Country Analysis
    • 7.4.1. China Human Insulin Market Outlook
      • 7.4.1.1. Market Size & Forecast
        • 7.4.1.1.1. By Value
      • 7.4.1.2. Market Share & Forecast
        • 7.4.1.2.1. By Indication
        • 7.4.1.2.2. By Brand
        • 7.4.1.2.3. By Route of Administration
        • 7.4.1.2.4. By Type
        • 7.4.1.2.5. By Onset Time
        • 7.4.1.2.6. By Products
    • 7.4.2. India Human Insulin Market Outlook
      • 7.4.2.1. Market Size & Forecast
        • 7.4.2.1.1. By Value
      • 7.4.2.2. Market Share & Forecast
        • 7.4.2.2.1. By Indication
        • 7.4.2.2.2. By Brand
        • 7.4.2.2.3. By Route of Administration
        • 7.4.2.2.4. By Type
        • 7.4.2.2.5. By Onset Time
        • 7.4.2.2.6. By Products
    • 7.4.3. Japan Human Insulin Market Outlook
      • 7.4.3.1. Market Size & Forecast
        • 7.4.3.1.1. By Value
      • 7.4.3.2. Market Share & Forecast
        • 7.4.3.2.1. By Indication
        • 7.4.3.2.2. By Brand
        • 7.4.3.2.3. By Route of Administration
        • 7.4.3.2.4. By Type
        • 7.4.3.2.5. By Onset Time
        • 7.4.3.2.6. By Products
    • 7.4.4. South Korea Human Insulin Market Outlook
      • 7.4.4.1. Market Size & Forecast
        • 7.4.4.1.1. By Value
      • 7.4.4.2. Market Share & Forecast
        • 7.4.4.2.1. By Indication
        • 7.4.4.2.2. By Brand
        • 7.4.4.2.3. By Route of Administration
        • 7.4.4.2.4. By Type
        • 7.4.4.2.5. By Onset Time
        • 7.4.4.2.6. By Products
    • 7.4.5. Singapore Human Insulin Market Outlook
      • 7.4.5.1. Market Size & Forecast
        • 7.4.5.1.1. By Value
      • 7.4.5.2. Market Share & Forecast
        • 7.4.5.2.1. By Indication
        • 7.4.5.2.2. By Brand
        • 7.4.5.2.3. By Route of Administration
        • 7.4.5.2.4. By Type
        • 7.4.5.2.5. By Onset Time
        • 7.4.5.2.6. By Products
    • 7.4.6. Australia Human Insulin Market Outlook
      • 7.4.6.1. Market Size & Forecast
        • 7.4.6.1.1. By Value
      • 7.4.6.2. Market Share & Forecast
        • 7.4.6.2.1. By Indication
        • 7.4.6.2.2. By Brand
        • 7.4.6.2.3. By Route of Administration
        • 7.4.6.2.4. By Type
        • 7.4.6.2.5. By Onset Time
        • 7.4.6.2.6. By Products

8. Europe Human Insulin Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Indication
    • 8.2.2. By Brand
    • 8.2.3. By Route of Administration
    • 8.2.4. By Type
    • 8.2.5. By Onset Time
    • 8.2.6. By Products
    • 8.2.7. By Country
  • 8.3. Market Attractiveness Index
  • 8.4. Europe: Country Analysis
    • 8.4.1. France Human Insulin Market Outlook
      • 8.4.1.1. Market Size & Forecast
        • 8.4.1.1.1. By Value
      • 8.4.1.2. Market Share & Forecast
        • 8.4.1.2.1. By Indication
        • 8.4.1.2.2. By Brand
        • 8.4.1.2.3. By Route of Administration
        • 8.4.1.2.4. By Type
        • 8.4.1.2.5. By Onset Time
        • 8.4.1.2.6. By Products
    • 8.4.2. Germany Human Insulin Market Outlook
      • 8.4.2.1. Market Size & Forecast
        • 8.4.2.1.1. By Value
      • 8.4.2.2. Market Share & Forecast
        • 8.4.2.2.1. By Indication
        • 8.4.2.2.2. By Brand
        • 8.4.2.2.3. By Route of Administration
        • 8.4.2.2.4. By Type
        • 8.4.2.2.5. By Onset Time
        • 8.4.2.2.6. By Products
    • 8.4.3. United Kingdom Human Insulin Market Outlook
      • 8.4.3.1. Market Size & Forecast
        • 8.4.3.1.1. By Value
      • 8.4.3.2. Market Share & Forecast
        • 8.4.3.2.1. By Indication
        • 8.4.3.2.2. By Brand
        • 8.4.3.2.3. By Route of Administration
        • 8.4.3.2.4. By Type
        • 8.4.3.2.5. By Onset Time
        • 8.4.3.2.6. By Products
    • 8.4.4. Italy Human Insulin Market Outlook
      • 8.4.4.1. Market Size & Forecast
        • 8.4.4.1.1. By Value
      • 8.4.4.2. Market Share & Forecast
        • 8.4.4.2.1. By Indication
        • 8.4.4.2.2. By Brand
        • 8.4.4.2.3. By Route of Administration
        • 8.4.4.2.4. By Type
        • 8.4.4.2.5. By Onset Time
        • 8.4.4.2.6. By Products
    • 8.4.5. Russia Human Insulin Market Outlook
      • 8.4.5.1. Market Size & Forecast
        • 8.4.5.1.1. By Value
      • 8.4.5.2. Market Share & Forecast
        • 8.4.5.2.1. By Indication
        • 8.4.5.2.2. By Brand
        • 8.4.5.2.3. By Route of Administration
        • 8.4.5.2.4. By Type
        • 8.4.5.2.5. By Onset Time
        • 8.4.5.2.6. By Products
    • 8.4.6. Spain Human Insulin Market Outlook
      • 8.4.6.1. Market Size & Forecast
        • 8.4.6.1.1. By Value
      • 8.4.6.2. Market Share & Forecast
        • 8.4.6.2.1. By Indication
        • 8.4.6.2.2. By Brand
        • 8.4.6.2.3. By Route of Administration
        • 8.4.6.2.4. By Type
        • 8.4.6.2.5. By Onset Time
        • 8.4.6.2.6. By Products

9. North America Human Insulin Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Indication
    • 9.2.2. By Brand
    • 9.2.3. By Route of Administration
    • 9.2.4. By Type
    • 9.2.5. By Onset Time
    • 9.2.6. By Products
    • 9.2.7. By Country
  • 9.3. Market Attractiveness Index
  • 9.4. North America: Country Analysis
    • 9.4.1. United States Human Insulin Market Outlook
      • 9.4.1.1. Market Size & Forecast
        • 9.4.1.1.1. By Value
      • 9.4.1.2. Market Share & Forecast
        • 9.4.1.2.1. By Indication
        • 9.4.1.2.2. By Brand
        • 9.4.1.2.3. By Route of Administration
        • 9.4.1.2.4. By Type
        • 9.4.1.2.5. By Onset Time
        • 9.4.1.2.6. By Products
    • 9.4.2. Mexico Human Insulin Market Outlook
      • 9.4.2.1. Market Size & Forecast
        • 9.4.2.1.1. By Value
      • 9.4.2.2. Market Share & Forecast
        • 9.4.2.2.1. By Indication
        • 9.4.2.2.2. By Brand
        • 9.4.2.2.3. By Route of Administration
        • 9.4.2.2.4. By Type
        • 9.4.2.2.5. By Onset Time
        • 9.4.2.2.6. By Products
    • 9.4.3. Canada Human Insulin Market Outlook
      • 9.4.3.1. Market Size & Forecast
        • 9.4.3.1.1. By Value
      • 9.4.3.2. Market Share & Forecast
        • 9.4.3.2.1. By Indication
        • 9.4.3.2.2. By Brand
        • 9.4.3.2.3. By Route of Administration
        • 9.4.3.2.4. By Type
        • 9.4.3.2.5. By Onset Time
        • 9.4.3.2.6. By Products

10. South America Human Insulin Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Indication
    • 10.2.2. By Brand
    • 10.2.3. By Route of Administration
    • 10.2.4. By Type
    • 10.2.5. By Onset Time
    • 10.2.6. By Products
    • 10.2.7. By Country
  • 10.3. Market Attractiveness Index
  • 10.4. South America: Country Analysis
    • 10.4.1. Brazil Human Insulin Market Outlook
      • 10.4.1.1. Market Size & Forecast
        • 10.4.1.1.1. By Value
      • 10.4.1.2. Market Share & Forecast
        • 10.4.1.2.1. By Indication
        • 10.4.1.2.2. By Brand
        • 10.4.1.2.3. By Route of Administration
        • 10.4.1.2.4. By Type
        • 10.4.1.2.5. By Onset Time
        • 10.4.1.2.6. By Products
    • 10.4.2. Argentina Human Insulin Market Outlook
      • 10.4.2.1. Market Size & Forecast
        • 10.4.2.1.1. By Value
      • 10.4.2.2. Market Share & Forecast
        • 10.4.2.2.1. By Indication
        • 10.4.2.2.2. By Brand
        • 10.4.2.2.3. By Route of Administration
        • 10.4.2.2.4. By Type
        • 10.4.2.2.5. By Onset Time
        • 10.4.2.2.6. By Products
    • 10.4.3. Colombia Human Insulin Market Outlook
      • 10.4.3.1. Market Size & Forecast
        • 10.4.3.1.1. By Value
      • 10.4.3.2. Market Share & Forecast
        • 10.4.3.2.1. By Indication
        • 10.4.3.2.2. By Brand
        • 10.4.3.2.3. By Route of Administration
        • 10.4.3.2.4. By Type
        • 10.4.3.2.5. By Onset Time
        • 10.4.3.2.6. By Products

11. Middle East and Africa Human Insulin Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value & Volume
  • 11.2. Market Share & Forecast
    • 11.2.1. By Indication
    • 11.2.2. By Brand
    • 11.2.3. By Route of Administration
    • 11.2.4. By Type
    • 11.2.5. By Onset Time
    • 11.2.6. By Products
    • 11.2.7. By Country
  • 11.3. Market Attractiveness Index
  • 11.4. MEA: Country Analysis
    • 11.4.1. South Africa Human Insulin Market Outlook
      • 11.4.1.1. Market Size & Forecast
        • 11.4.1.1.1. By Value
      • 11.4.1.2. Market Share & Forecast
        • 11.4.1.2.1. By Indication
        • 11.4.1.2.2. By Brand
        • 11.4.1.2.3. By Route of Administration
        • 11.4.1.2.4. By Type
        • 11.4.1.2.5. By Onset Time
        • 11.4.1.2.6. By Products
    • 11.4.2. Saudi Arabia Human Insulin Market Outlook
      • 11.4.2.1. Market Size & Forecast
        • 11.4.2.1.1. By Value
      • 11.4.2.2. Market Share & Forecast
        • 11.4.2.2.1. By Indication
        • 11.4.2.2.2. By Brand
        • 11.4.2.2.3. By Route of Administration
        • 11.4.2.2.4. By Type
        • 11.4.2.2.5. By Onset Time
        • 11.4.2.2.6. By Products
    • 11.4.3. UAE Human Insulin Market Outlook
      • 11.4.3.1. Market Size & Forecast
        • 11.4.3.1.1. By Value
      • 11.4.3.2. Market Share & Forecast
        • 11.4.3.2.1. By Indication
        • 11.4.3.2.2. By Brand
        • 11.4.3.2.3. By Route of Administration
        • 11.4.3.2.4. By Type
        • 11.4.3.2.5. By Onset Time
        • 11.4.3.2.6. By Products

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Players Profiled (Leading Companies)
    • 14.2.1. Nektar Therapeutics
    • 14.2.2. MannKind Corporation
    • 14.2.3. Novo Nordisk
    • 14.2.4. Physicians Total Care, Inc.
    • 14.2.5. Eli Lilly and Company
    • 14.2.6. A-S Medication Solutions
    • 14.2.7. REMEDYREPACK INC.
    • 14.2.8. Sedico Co.
    • 14.2.9. Sanofi Aventis
    • 14.2.10. Pfizer Inc.
    • 14.2.11. PerkinElmer
    • 14.2.12. Merck
    • 14.2.13. Biocon
    • 14.2.14. Wockhardt
    • 14.2.15. Julphal
    • 14.2.16. Ypsomed AG
    • 14.2.17. Becton Dickinson and Company
    • 14.2.18. B. Braun Melsungen AG
    • 14.2.19. Baxter
    • 14.2.20. Tandem Diabetes Care, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer